BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1038 related articles for article (PubMed ID: 10634817)

  • 1. Action of atorvastatin in combined hyperlipidemia : preferential reduction of cholesteryl ester transfer from HDL to VLDL1 particles.
    Guerin M; Lassel TS; Le Goff W; Farnier M; Chapman MJ
    Arterioscler Thromb Vasc Biol; 2000 Jan; 20(1):189-97. PubMed ID: 10634817
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dose-dependent action of atorvastatin in type IIB hyperlipidemia: preferential and progressive reduction of atherogenic apoB-containing lipoprotein subclasses (VLDL-2, IDL, small dense LDL) and stimulation of cellular cholesterol efflux.
    Guerin M; Egger P; Soudant C; Le Goff W; van Tol A; Dupuis R; Chapman MJ
    Atherosclerosis; 2002 Aug; 163(2):287-96. PubMed ID: 12052475
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fenofibrate reduces plasma cholesteryl ester transfer from HDL to VLDL and normalizes the atherogenic, dense LDL profile in combined hyperlipidemia.
    Guérin M; Bruckert E; Dolphin PJ; Turpin G; Chapman MJ
    Arterioscler Thromb Vasc Biol; 1996 Jun; 16(6):763-72. PubMed ID: 8640404
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preferential cholesteryl ester acceptors among triglyceride-rich lipoproteins during alimentary lipemia in normolipidemic subjects.
    Lassel TS; Guérin M; Auboiron S; Chapman MJ; Guy-Grand B
    Arterioscler Thromb Vasc Biol; 1998 Jan; 18(1):65-74. PubMed ID: 9445258
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pravastatin modulates cholesteryl ester transfer from HDL to apoB-containing lipoproteins and lipoprotein subspecies profile in familial hypercholesterolemia.
    Guérin M; Dolphin PJ; Talussot C; Gardette J; Berthézène F; Chapman MJ
    Arterioscler Thromb Vasc Biol; 1995 Sep; 15(9):1359-68. PubMed ID: 7670950
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lipid and apolipoprotein levels and distribution in patients with hypertriglyceridemia: effect of triglyceride reductions with atorvastatin.
    Le NA; Innis-Whitehouse W; Li X; Bakker-Arkema R; Black D; Brown WV
    Metabolism; 2000 Feb; 49(2):167-77. PubMed ID: 10690940
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Absence of cholesteryl ester transfer protein-mediated cholesteryl ester mass transfer from high-density lipoprotein to low-density lipoprotein particles is a major feature of combined hyperlipidaemia.
    Guérin M; Bruckert E; Dolphin PJ; Chapman MJ
    Eur J Clin Invest; 1996 Jun; 26(6):485-94. PubMed ID: 8817163
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Atorvastatin reduces postprandial accumulation and cholesteryl ester transfer protein-mediated remodeling of triglyceride-rich lipoprotein subspecies in type IIb hyperlipidemia.
    Guerin M; Egger P; Le Goff W; Soudant C; Dupuis R; Chapman MJ
    J Clin Endocrinol Metab; 2002 Nov; 87(11):4991-5000. PubMed ID: 12414863
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of pravastatin on apolipoprotein-specific high density lipoprotein subpopulations and low density lipoprotein subclass phenotypes in patients with primary hypercholesterolemia.
    Cheung MC; Austin MA; Moulin P; Wolf AC; Cryer D; Knopp RH
    Atherosclerosis; 1993 Aug; 102(1):107-19. PubMed ID: 8257447
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cholesteryl ester transfer activity in liver disease and cholestasis, and its relation with fatty acid composition of lipoprotein lipids.
    Iglesias A; Arranz M; Alvarez JJ; Perales J; Villar J; Herrera E; Lasunción MA
    Clin Chim Acta; 1996 Apr; 248(2):157-74. PubMed ID: 8740580
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preferential reduction of very low density lipoprotein-1 particle number by fenofibrate in type IIB hyperlipidemia: consequences for lipid accumulation in human monocyte-derived macrophages.
    Milosavljevic D; Griglio S; Le Naour G; Chapman MJ
    Atherosclerosis; 2001 Mar; 155(1):251-60. PubMed ID: 11223449
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of the cholesteryl ester transfer protein inhibitor torcetrapib on apolipoprotein B100 metabolism in humans.
    Millar JS; Brousseau ME; Diffenderfer MR; Barrett PH; Welty FK; Faruqi A; Wolfe ML; Nartsupha C; Digenio AG; Mancuso JP; Dolnikowski GG; Schaefer EJ; Rader DJ
    Arterioscler Thromb Vasc Biol; 2006 Jun; 26(6):1350-6. PubMed ID: 16574893
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of atorvastatin versus fenofibrate on apoB-100 and apoA-I kinetics in mixed hyperlipidemia.
    Bilz S; Wagner S; Schmitz M; Bedynek A; Keller U; Demant T
    J Lipid Res; 2004 Jan; 45(1):174-85. PubMed ID: 14523053
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of marine lipids on cholesteryl ester transfer and lipoprotein composition in patients with hypercholesterolemia.
    Bagdade JD; Ritter MC; Davidson M; Subbaiah PV
    Arterioscler Thromb; 1992 Oct; 12(10):1146-52. PubMed ID: 1390587
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alterations in composition and concentration of lipoproteins and elevated cholesteryl ester transfer in non-insulin-dependent diabetes mellitus (NIDDM).
    Elchebly M; Porokhov B; Pulcini T; Berthezène F; Ponsin G
    Atherosclerosis; 1996 Jun; 123(1-2):93-101. PubMed ID: 8782840
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Changes in LDL particle concentrations after treatment with the cholesteryl ester transfer protein inhibitor anacetrapib alone or in combination with atorvastatin.
    Krauss RM; Pinto CA; Liu Y; Johnson-Levonas AO; Dansky HM
    J Clin Lipidol; 2015; 9(1):93-102. PubMed ID: 25670366
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Action of ciprofibrate in type IIb hyperlipoproteinemia: modulation of the atherogenic lipoprotein phenotype and stimulation of high-density lipoprotein-mediated cellular cholesterol efflux.
    Guerin M; Le Goff W; Frisdal E; Schneider S; Milosavljevic D; Bruckert E; Chapman MJ
    J Clin Endocrinol Metab; 2003 Aug; 88(8):3738-46. PubMed ID: 12915663
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacological modulation of cholesteryl ester transfer protein, a new therapeutic target in atherogenic dyslipidemia.
    Le Goff W; Guerin M; Chapman MJ
    Pharmacol Ther; 2004 Jan; 101(1):17-38. PubMed ID: 14729390
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of atorvastatin on postprandial plasma lipoproteins in postinfarction patients with combined hyperlipidaemia.
    Boquist S; Karpe F; Danell-Toverud K; Hamsten A
    Atherosclerosis; 2002 May; 162(1):163-70. PubMed ID: 11947910
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cholesteryl ester transfer in hypercholesterolaemia: fasting and postprandial studies with and without pravastatin.
    Contacos C; Barter PJ; Vrga L; Sullivan DR
    Atherosclerosis; 1998 Nov; 141(1):87-98. PubMed ID: 9863541
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 52.